HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by KRYNETSKAIA, N. F. Articles by RELLING, M. V. Search for Related Content PubMed PubMed Citation Articles by KRYNETSKAIA, N. F. Articles by RELLING, M. V.

Thioguanine substitution alters DNA cleavage mediated by topoisomerase II

NATALIA F. KRYNETSKAIA^*, XIANGJUN CAI, JOHN L. NITISS, EUGENE Y. KRYNETSKI^*, and MARY V. RELLING^*,1

^* University of Tennessee and
St. Jude Children’s Research Hospital, Memphis 38105-2794, Tennessee, USA

¹Correspondence: Department of Pharmaceutical Science, St. Jude Children’s Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA. E-mail: mary.relling{at}stjude.org

Thiopurines and topoisomerase II-targeted drugs (e.g., etoposide) are widely used anticancer drugs. However, topoisomerase II-targeted drugs can cause acute myeloid leukemia, with the risk of this secondary leukemia linked to a genetic defect in thiopurine catabolism. Chronic thiopurines result in thioguanine substitution in DNA. The effect of these substitutions on DNA topoisomerase II activity is not known. Our goal was to determine whether deoxythioguanosine substitution alters DNA cleavage stabilized by human topoisomerase II. We studied four variations of a 40 mer oligonucleotide with a topoisomerase II cleavage site, each with a single deoxythioguanosine in a different position relative to the cleavage site (-1 or +2 in the top and +2 or +4 in the bottom strand). Deoxythioguanosine substitution caused position-dependent quantitative effects on cleavage. With the -1 or +2 top and +2 or +4 bottom substitutions, mean topoisomerase II-induced cleavage was 0.6-, 2.0-, 1.1-, and 3.3-fold that with the wild-type substrate (P=0.011, < 0.008, 0.51, and < 0.001, respectively). In the presence of 100 µM etoposide, cleavage was enhanced for wild-type and all thioguanosine-modified substrates relative to no etoposide, with the +4 bottom substitution showing greater etoposide-induced cleavage than the wild-type substrate (P=0.015). We conclude that thioguanine incorporation alters the DNA cleavage induced by topoisomerase II in the presence and absence of etoposide, providing new insights to the mechanism of thiopurine effect and on the leukemogenesis of thiopurines, with or without topoisomerase inhibitors.—Krynetskaia, N. F., Cai, X., Nitiss, J. L., Krynetski, E. Y., Relling, M. V. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.

Key Words: thioguanylated oligodeoxyribonucleotides • etoposide • thiopurine • leukemogenesis

This article has been cited by other articles:

				N. Krynetskaia, H. Xie, S. Vucetic, Z. Obradovic, and E. Krynetskiy High Mobility Group Protein B1 Is an Activator of Apoptotic Response to Antimetabolite Drugs Mol. Pharmacol., January 1, 2008; 73(1): 260 - 269. [Abstract] [Full Text] [PDF]

				G. Zaza, M. Cheok, W. Yang, J. C. Panetta, C.-H. Pui, M. V. Relling, and W. E. Evans Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment Blood, September 1, 2005; 106(5): 1778 - 1785. [Abstract] [Full Text] [PDF]

				J. Bohon and C. R. de los Santos Effect of 6-thioguanine on the stability of duplex DNA Nucleic Acids Res., May 19, 2005; 33(9): 2880 - 2886. [Abstract] [Full Text] [PDF]

				N. F. Krynetskaia, T. L. Brenner, E. Y. Krynetski, W. Du, J. C. Panetta, P. Ching-Hon, and W. E. Evans Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity in Msh2-/- Mice Mol. Pharmacol., August 1, 2003; 64(2): 456 - 465. [Abstract] [Full Text] [PDF]

				L. Somerville, E. Y. Krynetski, N. F. Krynetskaia, R. D. Beger, W. Zhang, C. A. Marhefka, W. E. Evans, and R. W. Kriwacki Structure and Dynamics of Thioguanine-modified Duplex DNA J. Biol. Chem., January 3, 2003; 278(2): 1005 - 1011. [Abstract] [Full Text] [PDF]

				E. Y. Krynetski, N. F. Krynetskaia, M. E. Bianchi, and W. E. Evans A Nuclear Protein Complex Containing High Mobility Group Proteins B1 and B2, Heat Shock Cognate Protein 70, ERp60, and Glyceraldehyde-3-Phosphate Dehydrogenase Is Involved in the Cytotoxic Response to DNA Modified by Incorporation of Anticancer Nucleoside Analogues Cancer Res., January 1, 2003; 63(1): 100 - 106. [Abstract] [Full Text] [PDF]

				W. L. Carroll, D. Bhojwani, D.-J. Min, E. Raetz, M. Relling, S. Davies, J. R. Downing, C. L. Willman, and J. C. Reed Pediatric Acute Lymphoblastic Leukemia Hematology, January 1, 2003; 2003(1): 102 - 131. [Abstract] [Full Text] [PDF]

				D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF]

				N. F. KRYNETSKAIA, J. Y. FENG, E. Y. KRYNETSKI, J. V. GARCIA, J. C. PANETTA, K. S. ANDERSON, and W. E. EVANS Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug FASEB J, September 1, 2001; 15(11): 1902 - 1908. [Abstract] [Full Text] [PDF]